Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Quidel to Hold Second Quarter 2010 Results Conference Call on July 29, 2010

SAN DIEGO, Jul 08, 2010 (BUSINESS WIRE) --

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic tests, will release second quarter 2010 financial results after market close on Thursday, July 29, 2010.

Following the release of results, Douglas C. Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions.

To participate in the live call by telephone from the U.S., dial (800) 599-9829, or from outside the U.S. dial (617) 847-8703, and enter the pass code 41887153.

A live webcast of the call can be accessed at http://www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on July 29 by dialing (888) 286-8010 from the U.S., or (617) 801-6888 for international callers, and entering pass code 14058949.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of rapid diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to healthcare providers. Marketed under the leading brand names QuickVue(R),D3 Direct DetectionTM and ThyretainTM, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit http://www.quidel.com and Diagnostic Hybrids at http://www.dhiusa.com.

SOURCE: Quidel Corporation

Quidel Corporation
John M. Radak, Chief Financial Officer
858-646-8032
or
Media and Investors Contact:
Ruben Argueta
Investor Relations Manager
858-552-1100 x1139
rargueta@quidel.com